In an interview with Technology Networks, Dr. Daniel Reker discusses how machine learning is improving data-scarce areas of drug discovery.

It’s no longer about hiring specialists. The market now demands hybrid marketers: people who can speak to both business goals ...

Evolving toxicity assessments for engineered nanoparticles underline the importance of predictive models and life-cycle risk ...

How has crypto market manipulation evolved? Beyond wash trading, know how liquidity spoofing, social signal engineering, and ...

Gary Marcus advocates caution about AI's risks. He told Business Insider that using OpenClaw was like giving your passwords ...